Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 2
2006 1
2007 2
2008 4
2010 4
2011 4
2012 4
2013 6
2014 8
2015 8
2016 13
2017 8
2018 4
2019 4
2020 8
2021 15
2022 7
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors.
Takagi M, Ogawa C, Iehara T, Aoki-Nogami Y, Ishibashi E, Imai M, Kimura T, Nagata M, Yasuhara M, Masutani M, Yoshimura K, Tomizawa D, Ogawa A, Yonemori K, Morishita A, Miyamoto S, Takita J, Kihara T, Nobori K, Hasebe K, Miya F, Ikeda S, Shioda Y, Matsumoto K, Fujimura J, Mizutani S, Morio T, Hosoi H, Koike R. Takagi M, et al. Among authors: nagata m. Cancer. 2022 Aug 1;128(15):2949-2957. doi: 10.1002/cncr.34270. Epub 2022 May 20. Cancer. 2022. PMID: 35593736 Free article. Clinical Trial.
The antioxidative stress regulator Nrf2 potentiates radioresistance of oral squamous cell carcinoma accompanied with metabolic modulation.
Matsuoka Y, Yoshida R, Kawahara K, Sakata J, Arita H, Nkashima H, Takahashi N, Hirayama M, Nagata M, Hirosue A, Kuwahara Y, Fukumoto M, Toya R, Murakami R, Nakayama H. Matsuoka Y, et al. Among authors: nagata m. Lab Invest. 2022 Aug;102(8):896-907. doi: 10.1038/s41374-022-00776-w. Epub 2022 Apr 12. Lab Invest. 2022. PMID: 35414650 Free PMC article.
Tumor Growth Suppression With Novel Intra-arterial Chemotherapy Using Epirubicin-entrapped Water-in-oil-in-water Emulsion In Vivo.
Yanagie H, Fujino T, Yanagawa M, Terao T, Imagawa T, Fujihara M, Morishita Y, Mizumachi R, Murata Y, Dewi N, Ono Y, Ikushima I, Seguchi K, Nagata M, Nonaka Y, Furuya Y, Hisa T, Nagasaki T, Arimori K, Nakashima T, Sugihara T, Kakimi K, Ono M, Nakajima J, Eriguchi M, Higashi S, Takahashi H. Yanagie H, et al. Among authors: nagata m. In Vivo. 2021 Jan-Feb;35(1):239-248. doi: 10.21873/invivo.12252. In Vivo. 2021. PMID: 33402470 Free PMC article.
An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma.
Gohara S, Shinohara K, Yoshida R, Kariya R, Tazawa H, Hashimoto M, Inoue J, Kubo R, Nakashima H, Arita H, Kawaguchi S, Yamana K, Nagao Y, Iwamoto A, Sakata J, Matsuoka Y, Takeshita H, Hirayama M, Kawahara K, Nagata M, Hirosue A, Kuwahara Y, Fukumoto M, Okada S, Urata Y, Fujiwara T, Nakayama H. Gohara S, et al. Among authors: nagata m. Mol Ther Oncolytics. 2022 Oct 8;27:141-156. doi: 10.1016/j.omto.2022.10.001. eCollection 2022 Dec 15. Mol Ther Oncolytics. 2022. PMID: 36381653 Free PMC article.
Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors.
Kaneko S, Asahina Y, Nakagawa M, Murakawa M, Miyazaki Y, Asakage T, Fukuda S, Namiki T, Kano Y, Nagata M, Tsuchiya J, Miyoshi M, Kitahata-Kawai F, Nitta S, Itsui Y, Kakinuma S, Okamoto R. Kaneko S, et al. Among authors: nagata m. Hepatol Res. 2023 May;53(5):450-459. doi: 10.1111/hepr.13878. Epub 2023 Jan 27. Hepatol Res. 2023. PMID: 36626292
91 results